Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting

Journal of Vascular Surgery

Volumn 51, Issue 4, 2010, Pages 926-932

  Davies, Mark G ^a   Saad, Wael E ^a   Bismuth, Jean ^a   Naoum, Joseph J ^a   Peden, Eric K ^a   Lumsden, Alan B ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOPPLER ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; STENT; SURVIVAL RATE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR PATENCY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RENAL ARTERY OBSTRUCTION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR PATENCY;

EID: 77949915979     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.09.042     Document Type: Article

References (33)

1. Zeller T. Current state of diagnosis and endovascular treatment of renal artery stenosis. Vasa 35 (2006) 147-155
2. Hansen K.J., Cherr G.S., Craven T.E., Motew S.J., Travis J.A., Wong J.M., et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. J Vasc Surg 32 (2000) 472-482
3. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 287 (2002) 356-359
4. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
5. Sarafidis P.A. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 17 (2008) 450-456
6. Clavijo L.C., Pinto T.L., Kuchulakanti P.K., Torguson R., Chu W.W., Satler L.F., et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 7 (2006) 7-11
7. Zeller M., Steg P.G., Ravisy J., Laurent Y., Janin-Manificat L., L'Huillier I., et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 165 (2005) 1192-1198
8. Scuteri A., Najjar S.S., Muller D.C., Andres R., Hougaku H., Metter E.J., and Lakatta E.G. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 43 (2004) 1388-1395
9. Palomo I., Alarcon M., Moore-Carrasco R., and Argiles J.M. Hemostasis alterations in metabolic syndrome. Int J Mol Med 18 (2006) 969-974
10. Anand S.S., Yi Q., Gerstein H., Lonn E., Jacobs R., Vuksan V., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
11. Wallenfeldt K., Hulthe J., and Fagerberg B. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med 258 (2005) 28-37
12. Iannuzzi A., De Michele M., Bond M.G., Sacchetti L., Fortunato G., Salvatore F., et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the "Progetto ATENA" study). Am J Cardiol 96 (2005) 1162-1165
13. Wei Y.D., Hu D.Y., Zhang R.F., Zheng L.Q., Li J., Yu J.M., and Xing Y. Metabolic syndrome complicated by peripheral arterial disease: clinical study of 2115 cases. Zhonghua Yi Xue Za Zhi 86 (2006) 2114-2116
14. Protack C.D., Bakken A.M., Xu J., Saad W.E., Lumsden A.B., and Davies M.G. Metabolic syndrome: a predictor of adverse events after carotid revascularization. J Vasc Surg 49 (2009) 1172-1180
15. Grundy S.M., Brewer H.B.J., Cleeman J.I., and Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
16. Yutan E., Glickerman D.J., Caps M.T., Hatsukami T., Harley J.D., and Davies M.G. Percutaneous transluminal revascularization for renal artery stenosis: Veterans Affairs Puget Sound Health Care System experience. J Vasc Surg 34 (2001) 685-693
17. Sivamurthy N., Suroweic S.M., Culakova E., Rhodes J.M., Lee D., Sternbach Y., et al. Divergent outcomes after percutaneous therapy for symptomatic renal artery stenosis. J Vasc Surg 39 (2004) 565-574
18. Galaria I.I., Surowiec S.M., Rhodes J.M., Illig K.A., Shortell C.K., Sternbach Y., et al. Percutaneous and open renal revascularizations have equivalent long-term functional outcomes. Ann Vasc Surg 19 (2005) 218-228
19. Rundback J.H., Sacks D., Kent K.C., Cooper C., Jones C., Murphy T.P., et al. Guidelines for the reporting of renal artery revascularization in clinical trials. Circulation 106 (2002) 1572-1585
20. Natali A., Pucci G., Boldrini B., and Schillaci G. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol 22 (2009) 29-38
21. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
22. Einhorn D., Reaven G.M., Cobin R.H., Ford E.S., Ganda O.P., Handelsman Y., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
23. Bloomgarden Z.T. Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care 27 (2004) 824-830
24. Executive Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
25. Lev-Ran A. Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev 17 (2001) 347-362
26. Sarafidis P.A., and Ruilope L.M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 26 (2006) 232-244
27. Corpeleijn E., Bakker S.J., and Stolk R.P. Obesity and impaired renal function: potential for lifestyle intervention?. Eur J Epidemiol 24 (2009) 275-280
28. Kramer H., and Luke A. Obesity and kidney disease: a big dilemma. Curr Opin Nephrol Hypertens 16 (2007) 237-241
29. Brevetti G., Schiano V., Sirico G., Giugliano G., Laurenzano E., and Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 44 (2006) 101-107
30. Maksimovic M., Vlajinac H., Radak D., Marinkovic J., and Jorga J. Relationship between peripheral arterial disease and metabolic syndrome. Angiology 60 (2009) 546-553
31. Zierler R.E., Bergelin R.O., Davidson R.C., Cantwell-Gab K., Polissar N.L., and Strandness D.E.J. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertension 9 (1996) 1055-1061
32. Hoffmann R., Stellbrink E., Schröder J., Grawe A., Vogel G., Blindt R., et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol 100 (2007) 1347-1352
33. Canibus P., Faloia E., Piva T., Muçai A., Serenelli M., Perna G.P., et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism 57 (2008) 593-597